Product details
Catalog number BNUB0884-100
Price for BNUB0884-100
Size / count 1x 100 µL
Bromodeoxyuridine (BrdU) is a synthetic nucleoside thymidine analog. It is commonly used to detect proliferation in cells. In cells cultured in the presence of BrdU, BrdU will incorporate into newly synthesized DNA during S-phase. Antibodies specific for BrdU can then be used to detect replicated DNA. This antibody is available purified, with BSA (0.2 mg/mL) or purified, BSA-free (1 mg/mL) .
The catalog number for BrdU (Bromodeoxyuridine) (MoBu-1), 0.2mg/mL is BNUB0884-100.
BrdU (Bromodeoxyuridine) (MoBu-1), 0.2mg/mL is available in the following size(s): 1x 100 µL.
BrdU (Bromodeoxyuridine) (MoBu-1), 0.2mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.
BrdU (Bromodeoxyuridine) (MoBu-1), 0.2mg/mL is manufactured by Biotium.
Estimated delivery time for BrdU (Bromodeoxyuridine) (MoBu-1), 0.2mg/mL is approximately 15 business day(s), depending on your location.
The safety data sheet for BrdU (Bromodeoxyuridine) (MoBu-1), 0.2mg/mL is available here: https://cdn.gentaur.com/products/37/68dd0295061270361e0ffd56/msds/bnub0884-100.pdf.
Bromodeoxyuridine (BrdU) is a synthetic nucleoside thymidine analog. It is commonly used to detect proliferation in cells. In cells cultured in the presence of BrdU, BrdU will incorporate into newly synthesized DNA during S-phase. Antibodies specific for BrdU can then be used to detect replicated DN
Endotoxin testing status is noted on the datasheet where applicable, particularly for recombinant proteins intended for cell-based or functional assays. If this isn’t listed and you need confirmation, contact support with the catalogue number.
Additional data may be available on request. Contact our technical support team with the catalogue number and we’ll check what supporting documentation the supplier can provide.
If the product is subject to intellectual property protections, we’ll advise on any MTA or usage restrictions before shipping. Let us know your intended end use so we can confirm what’s required upfront.